ライフサイエンスコーパス: remain to be seen

1 The health ramifications of our findings remain to be seen.

2 leads to neurological pathology and symptoms remain to be seen.

3 th in patients receiving long-term treatment remains to be seen.

4 Whether these associations are causal remains to be seen.

5 ul this approach will ultimately prove to be remains to be seen.

6 HF risk prediction or targets for prevention remains to be seen.

7 s of these models and classification schemes remains to be seen.

8 al biological significance of these products remains to be seen.

9 ersimplification of the correlation approach remains to be seen.

10 health benefits to other countries worldwide remains to be seen.

11 d convergence of (any) two bacterial species remains to be seen.

12 s replication in seronegative human subjects remains to be seen.

13 mal translate into true benefit for patients remains to be seen.

14 rent limitations in measurement sensitivity, remains to be seen.

15 these abilities have communicative relevance remains to be seen.

16 s that are models of adaptive sophistication remains to be seen.

17 nosuppressive agents on the incidence of RLN remains to be seen.

18 ly reduced Notch signaling in vivo, however, remains to be seen.

19 are involved in the aetiology of depression remains to be seen.

20 but the overall effect on long-term survival remains to be seen.

21 ntage in designing more effective immunogens remains to be seen.

22 activity that preceded occupation of MAN-44 remains to be seen.

23 l prove to have been necessary or sufficient remains to be seen.

24 s will translate into real clinical advances remains to be seen.

25 ions of alpha-melanocyte-stimulating hormone remains to be seen.

26 Whether these favorable trends will continue remains to be seen.

27 ry, however, the realization of this promise remains to be seen.

28 s-leukemia effects and disease-free survival remains to be seen.

29 Whether this is structural and/or regulatory remains to be seen.

30 these non-vaccine types will have on disease remains to be seen, but clearly continued efforts at cha

31 strong kinesin tail-microtubule interaction remains to be seen, but it is likely to play an importan

32 h enduring effects extend to other disorders remains to be seen, but the capacity to reduce risk foll

33 However, it remains to be seen how assortativity may influence the r

34 It remains to be seen how effective this information-intens

35 ructure is the central piece in a puzzle; it remains to be seen how it will fit together with other d

36 It remains to be seen how many cases of recurrent non-multi

37 However, it remains to be seen if all types of vaccines against HSV

38 It remains to be seen if any association between AHSP and c

39 valence-screening data are available, and it remains to be seen if CT will truly reduce mortality.

40 However, it remains to be seen if NMDAR hypofunction in PV+ neurons

41 may be ligand-binding receptors, although it remains to be seen if phospholipids or possibly other mo

42 It remains to be seen if the effects observed here-caused b

43 mber of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycle

44 It remains to be seen if vinculin can be phosphorylated at

45 What remains to be seen is whether fetal surgery and the note

46 uences of this substrate-induced aggregation remain to be seen, it has the potential to play a role i

47 Grb10 are consistent with this idea, but it remains to be seen just how general the pattern is.

48 However, it remains to be seen to what extent sexual theories and pr

49 It remains to be seen to what extent these inter-ST differe

50 It remains to be seen whether a similar outcome could be ob

51 It remains to be seen whether academia, government laborato

52 ontrol the pace of drug release; however, it remains to be seen whether an autocatalytic-based drug d

53 It remains to be seen whether early burst or ecological opp

54 different from those of other organs, and it remains to be seen whether flower waxes have composition

55 ol corrects the malabsorption of calcium, it remains to be seen whether higher amounts of vitamin D c

56 y the depletion of intracellular Cl-, but it remains to be seen whether it is mediated predominantly

57 It remains to be seen whether LESS or NOTES will prove thei

58 In light of the evidence, it remains to be seen whether mental practice with motor im

59 It remains to be seen whether more recent viruses with this

60 It remains to be seen whether one or both of these autoanti

61 genetic relationship of these two hosts, it remains to be seen whether or not this conservation of s

62 It remains to be seen whether perturbations of cellular hom

63 It remains to be seen whether pharmacological enhancement o

64 It remains to be seen whether preoperative serum anti-TNFal

65 It remains to be seen whether public-sector reforms will af

66 It remains to be seen whether the expression of the 43-kd i

67 , as GHB can also be metabolized to GABA, it remains to be seen whether the many GABAB receptor-media

68 ting properties have been attributed, but it remains to be seen whether the PH domain is involved in

69 e carbon and nitrogen fractionations, but it remains to be seen whether the specific effects observed

70 It remains to be seen whether there is a physiological coun

71 It remains to be seen whether these alterations arise local

72 It remains to be seen whether these differences in cellular

73 It remains to be seen whether these new findings will alter

74 However, it remains to be seen whether this antisense transcript pro

75 It remains to be seen whether this is true for other human

76 l in a large number of diabetic patients, it remains to be seen whether those who are preparing the E

77 Although it remains to be seen whether use of mammalian target of ra

78 It remains to be seen whether, on longer follow-up, there i

79 It remains to be seen whether, ultimately, science will tru

80 and pacemaker (PM) cardiomyocytes (CMs), it remains to be seen which subtypes are generated by direc

81 It remains to be seen which techniques will eventually beco

82 ons are limited in CRPC and survival benefit remains to be seen with the new therapies.